Skip to main content
Premium Trial:

Request an Annual Quote

Genomics Collaborative and Celestar-Lexico to Develop Breast Cancer Gene Expression Image Database

NEW YORK, March31 (GenomeWeb News) - Genomics Collaborative and Celestar-Lexico Sciences of Japan will collaborate to create a breast cancer gene expression image database, the companies said today.


In a pilot study, scientists will study the expression of a small number of relevant genes in cancerous and normal tissues, using Celestar's Large-scale in situ Hybridization technology and GCI's Global Repository of human biological samples. The companies selected the genes using Celestar's text mining system, MedTAK. Depending on the success of the pilot study, the companies plan to expand the expression database and eventually market it to pharmaceutical companies.


Celestar's LisH technology visualizes messenger RNA at the cellular level. GCI's repository contains 550,000 human tissue, DNA, and serum samples from 120,000 patients worldwide.

The Scan

Drug Response Variants May Be Distinct in Somatic, Germline Samples

Based on variants from across 21 drug response genes, researchers in The Pharmacogenomics Journal suspect that tumor-only DNA sequences may miss drug response clues found in the germline.

Breast Cancer Risk Gene Candidates Found by Multi-Ancestry Low-Frequency Variant Analysis

Researchers narrowed in on new and known risk gene candidates with variant profiles for almost 83,500 individuals with breast cancer and 59,199 unaffected controls in Genome Medicine.

Health-Related Quality of Life Gets Boost After Microbiome-Based Treatment for Recurrent C. Diff

A secondary analysis of Phase 3 clinical trial data in JAMA Network Open suggests an investigational oral microbiome-based drug may lead to enhanced quality of life measures.

Study Follows Consequences of Early Confirmatory Trials for Accelerated Approval Indications

Time to traditional approval or withdrawal was shorter when confirmatory trials started prior to accelerated approval, though overall regulatory outcomes remained similar, a JAMA study finds.